Search

Gossamer Bio Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

10.61 7,478.57

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.46

Max

10.74

Pagrindiniai rodikliai

By Trading Economics

Pajamos

64M

17M

Pardavimai

-7.7M

9.2M

Pelnas, tenkantis vienai akcijai

-0.2

Pelno marža

182.94

Darbuotojai

161

EBITDA

-28M

-71M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-90.03% downside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-391K

86M

Ankstesnė atidarymo kaina

-7467.96

Ankstesnė uždarymo kaina

10.61

Naujienos nuotaikos

By Acuity

79%

21%

314 / 339 reitingas Healthcare

Gossamer Bio Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-11 23:01; UTC

Gossamer Bio Inc. shares are higher in after-hours trading, reflecting a notable increase since Friday's close amid positive market sentiment following a narrower U.S. budget deficit.

2026-09-10 23:31; UTC

Event

Gossamer Bio Inc. shares rose in after-market trading following a 1-for-80 reverse stock split, advancing from earlier levels despite broader market dynamics.

2026-09-09 23:53; UTC

Gossamer Bio Inc. shares are lower in after-market hours following a significant decline since Wednesday's close, despite an earlier attempt to recover.

2026-09-04 19:26; UTC

Gossamer Bio shares are lower today amid increased selling pressure on risk assets, influenced by strong jobs data and rising interest rate expectations.

2026-09-03 23:26; UTC

Gossamer Bio Inc shares are lower in after-market hours, with no specific news identified for the decline. Major indices rose amid reduced interest rate hike expectations.

2026-09-02 23:06; UTC

Gossamer Bio Inc. shares are higher in after-market trading, remaining above their 20-day moving average and within the one-month trading range.

2026-09-01 23:06; UTC

Gossamer Bio Inc. shares declined in after-market trading, influenced by rising oil prices and inflation concerns amid a broader performance below the 20-day moving average.

2026-08-31 20:07; UTC

Gossamer Bio Inc is higher today amid broader market reactions to potential Federal Reserve interest rate hikes following remarks from Warsh at the Jackson Hole symposium.

2026-08-28 23:06; UTC

Gossamer Bio Inc. shares are higher in after-market trading, reflecting positive momentum since Friday's close amid broader market volatility.

2026-08-27 23:01; UTC

News

Gossamer Bio announced a private placement that could yield up to $250 million, with an initial $25 million expected upfront. Shares are roughly flat in after-market hours.

2026-08-26 23:01; UTC

Gossamer Bio Inc is higher in after-market trading, reflecting broader market gains amid positive economic data on personal consumption and durable goods orders.

2026-08-25 23:01; UTC

Gossamer Bio shares were lower in after-market hours, with no specific news identified. The broader market retreated after an initial advance amid falling crude oil prices.

2026-08-24 23:01; UTC

Gossamer Bio Inc. shares are lower in after-market trading amid notable volatility and ongoing geopolitical tensions involving the U.S. and Iran.

2026-08-22 00:01; UTC

Gossamer Bio Inc. shares advanced in after-market trading, recovering from earlier lows amid broader market gains despite no specific company news identified.

2026-08-21 23:01; UTC

Gossamer Bio Inc shares are higher in after-market hours, following broader market gains despite earlier lower trading. No specific news was identified for the move.

2026-08-20 23:01; UTC

Gossamer Bio shares are lower in after-market trading, reflecting broader market pressures following Walmart's disappointing sales growth and guidance.

2026-08-19 23:01; UTC

Gossamer Bio Inc shares are higher in after-market hours, following a notable peak earlier in the session. The stock remains below its 20-day moving average.

2026-08-18 23:01; UTC

Gossamer Bio Inc shares rose in after-market trading following Tuesday's close, though no specific news was identified to explain the movement.

2026-08-17 23:31; UTC

Gossamer Bio Inc shares are sharply higher in after-market trading, rising significantly despite being below its 20-day moving average and recent declines.

2026-08-15 00:01; UTC

Gossamer Bio Inc shares are higher in after-market hours, though no specific news explains the movement. The price remains below its 20-day moving average.

2026-08-14 22:51; UTC

Gossamer Bio Inc. shares are higher in after-market hours, despite disappointing U.S. retail sales data influencing broader market sentiment.

2026-08-13 23:01; UTC

News

Gossamer Bio reported second-quarter net income of $16.9 million and plans to submit a New Drug Application for seralutinib in September 2026. Shares are higher in after-market trading.

2026-08-12 23:01; UTC

Gossamer Bio Inc. shares advanced in after-market trading, continuing a strong performance since July 13, despite earlier fluctuations during the session.

2026-08-11 23:11; UTC

No specific news was identified for Gossamer Bio Inc. in after-market trading, with shares effectively unchanged since Tuesday's close.

2026-08-10 23:01; UTC

Gossamer Bio Inc. shares are higher in after-hours trading, reflecting strong performance and positioning above the 20-day moving average. No specific news was identified.

2026-08-07 19:56; UTC

Gossamer Bio Inc shares are higher today amid a weaker jobs report, easing interest rate hike concerns and shifting market sentiment towards a dovish outlook.

2026-08-06 23:12; UTC

Gossamer Bio Inc. shares are effectively unchanged in after-market trading, remaining flat within a narrow band. The stock is above its 20-day moving average.

2026-08-05 23:36; UTC

Gossamer Bio Inc shares are higher in after-market trading, despite no specific news. The stock is also above its 20-day moving average.

2026-08-04 23:01; UTC

Gossamer Bio shares declined after-market, reflecting broader market trends amid falling crude oil prices. Volatility was noted with fluctuations in trading.

2026-08-03 23:06; UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

Akcijų palyginimas

Kainos pokytis

Gossamer Bio Inc Prognozė

Kainos tikslas

By TipRanks

-90.03% į apačią

12 mėnesių prognozė

Vidutinis 1.07 USD  -90.03%

Aukščiausias 2 USD

Žemiausias 0.28 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Gossamer Bio Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

2

Pirkti

2

Laikyti

1

Parduoti

Rinkos nuotaikos

By Acuity

314 / 339 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

$

Apie bendrovę Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
help-icon Live chat